Benzinga | Sep 15, 2021 09:05AM EDT

AbCellera Announces Collaboration With Moderna To 'Discover Therapeutic Antibodies for mRNA Medicines'

Partnership combines AbCellera's AI-powered antibody discovery platform with Moderna's mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications

AbCellera (NASDAQ:ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.

"Over the past year, Moderna has demonstrated the speed and impact of its mRNA vaccine technology in helping to protect people around the world," said Carl Hansen, Ph.D., CEO and President of AbCellera. "We are excited to work alongside their team to advance RNA-encoded antibodies as a new frontier in genetic medicines."

Under the terms of the agreement, Moderna will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Moderna downstream clinical and commercial milestone payments and royalties on net sales of products.